Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Maureen Laverty is active.

Publication


Featured researches published by Maureen Laverty.


Journal of Endocrinology | 2009

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

Hong Lan; Galya Vassileva; Aaron Corona; Li Liu; Hana E. Baker; Andrei Golovko; Susan J. Abbondanzo; Weiwen Hu; Shijun Yang; Yun Ning; Robert A. Del Vecchio; Frederique Poulet; Maureen Laverty; Eric L. Gustafson; Joseph A. Hedrick; Timothy J. Kowalski

G protein-coupled receptor 119 (GPR119) is expressed in pancreatic islets and intestine, and is involved in insulin and incretin hormone release. GPR119-knockout (Gpr119(-/-)) mice were reported to have normal islet morphology and normal size, body weight (BW), and fed/fasted glucose levels. However, the physiological function of GPR119 and its role in maintaining glucose homeostasis under metabolic stress remain unknown. Here, we report the phenotypes of an independently generated line of Gpr119(-/-) mice under basal and high-fat diet (HFD)-induced obesity. Under low-fat diet feeding, Gpr119(-/-) mice show normal plasma glucose and lipids, but have lower BWs and lower post-prandial levels of active glucagon-like peptide 1 (GLP-1). Nutrient-stimulated GLP-1 release is attenuated in Gpr119(-/-) mice, suggesting that GPR119 plays a role in physiological regulation of GLP-1 secretion. Under HFD-feeding, both Gpr119(+)(/)(+) and Gpr119(-/-) mice gain weight similarly, develop hyperinsulinemia and hyperleptinemia, but not hyperglycemia or dyslipidemia. Glucose and insulin tolerance tests did not reveal a genotypic difference. These data show that GPR119 is not essential for the maintenance of glucose homeostasis. Moreover, we found that oleoylethanolamide (OEA), reported as a ligand for GPR119, was able to suppress food intake in both Gpr119(+)(/)(+) and Gpr119(-/-) mice, indicating that GPR119 is not required for the hypophagic effect of OEA. Our results demonstrate that GPR119 is important for incretin and insulin secretion, but not for appetite suppression.


Archives of Dermatological Research | 2010

Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions

Shu-Cheng Chen; Marjan de Groot; David Kinsley; Maureen Laverty; Terrill K. McClanahan; Maria G. Arreaza; Eric L. Gustafson; Marcel B. M. Teunissen; Menno A. de Rie; Jay S. Fine; Maarten C. Kraan

In psoriasis, leukocytes that infiltrate skin lesions have been shown to be involved in the pathogenesis of this disease. Previous investigations reporting the presence of CXCR3+ T lymphocytes in psoriatic lesional skin have suggested a role of this receptor in the recruitment of T cells into the lesion. The purpose of this study was to quantify the mRNA levels of CXCR3 and to perform a systematic analysis of the cell populations that express CXCR3 in human lesional and non-lesional psoriatic biopsies. We showed by real-time reverse transcriptase-polymerase chain reaction that the mRNA levels of CXCR3 and its ligands, CXCL9-11, were significantly elevated in psoriatic lesions, as compared to non-lesional samples. Serial cryostat sections of psoriasis skin biopsies were evaluated by immunohistochemistry. The number of CXCR3+ cells was low in non-lesional tissues. Quantitative image analysis demonstrated significant increases in the number of both epidermal and dermal CXCR3+ cells in lesional compared with non-lesional biopsies. The majority of CXCR3+ cells were located in the dermis of the lesional skin and 74% were demonstrated to be CD3+ T lymphocytes. A small number of CXCR3+ cells were CD68+ myeloid cells. In addition, we found that nearly all BDCA-2+ plasmacytoid dendritic cells in the psoriatic biopsies were CXCR3+. These findings support and extend prior reports suggesting the potential role for CXCR3 in the pathophysiology of plaque psoriasis, by mediating the recruitment of plasmacytoid dendritic cells and T cells into the developing lesions.


Mammalian Genome | 2003

Peppat, a pattern-based oligopeptide homology search method and the identification of a novel tachykinin-like peptide

Ying Jiang; Gang Fang; Eric L. Gustafson; Maureen Laverty; Yanbin Yin; Yong Zhang; Jingchu Luo; Jonathan Greene; Marvin Bayne; Joseph A. Hedrick; Nicholas J. Murgolo

PepPat, a hybrid method that combines pattern matching with similarity scoring, is described. We also report PepPats application in the identification of a novel tachykinin-like peptide. PepPat takes as input a query peptide and a user-specified regular expression pattern within the peptide. It first performs a database pattern match and then ranks candidates on the basis of their similarity to the query peptide. PepPat calculates similarity over the pattern spanning region, enhancing PepPats sensitivity for short query peptides. PepPat can also search for a user-specified number of occurrences of a repeated pattern within the target sequence. We illustrate PepPats application in short peptide ligand mining. As a validation example, we report the identification of a novel tachykinin-like peptide, C14TKL-1, and show it is an NK1 (neuokinin receptor 1) agonist whose message is widely expressed in human periphery. Availability: PepPat is offered online at: http://peppat.cbi.pku.edu.cn


Molecular Neurodegeneration | 2017

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Nicholas B. Hastings; Xiaohai Wang; Lixin Song; Brent D. Butts; Diane Grotz; Richard Hargreaves; J. Fred Hess; Kwok-Lam Karen Hong; Cathy Ruey-Ruey Huang; Lynn A. Hyde; Maureen Laverty; Julie Lee; Diane Levitan; Sherry X. Lu; Maureen Maguire; Veeravan Mahadomrongkul; Ernest McEachern; Xuesong Ouyang; Thomas W. Rosahl; Harold G. Selnick; Michaela Stanton; Giuseppe Terracina; David J. Vocadlo; Ganfeng Wang; Joseph L. Duffy; Eric M. Parker; Lili Zhang

BackgroundHyperphosphorylation of microtubule-associated protein tau is a distinct feature of neurofibrillary tangles (NFTs) that are the hallmark of neurodegenerative tauopathies. O-GlcNAcylation is a lesser known post-translational modification of tau that involves the addition of N-acetylglucosamine onto serine and threonine residues. Inhibition of O-GlcNAcase (OGA), the enzyme responsible for the removal of O-GlcNAc modification, has been shown to reduce tau pathology in several transgenic models. Clarifying the underlying mechanism by which OGA inhibition leads to the reduction of pathological tau and identifying translatable measures to guide human dosing and efficacy determination would significantly facilitate the clinical development of OGA inhibitors for the treatment of tauopathies.MethodsGenetic and pharmacological approaches are used to evaluate the pharmacodynamic response of OGA inhibition. A panel of quantitative biochemical assays is established to assess the effect of OGA inhibition on pathological tau reduction. A “click” chemistry labeling method is developed for the detection of O-GlcNAcylated tau.ResultsSubstantial (>80%) OGA inhibition is required to observe a measurable increase in O-GlcNAcylated proteins in the brain. Sustained and substantial OGA inhibition via chronic treatment with Thiamet G leads to a significant reduction of aggregated tau and several phosphorylated tau species in the insoluble fraction of rTg4510 mouse brain and total tau in cerebrospinal fluid (CSF). O-GlcNAcylated tau is elevated by Thiamet G treatment and is found primarily in the soluble 55 kD tau species, but not in the insoluble 64 kD tau species thought as the pathological entity.ConclusionThe present study demonstrates that chronic inhibition of OGA reduces pathological tau in the brain and total tau in the CSF of rTg4510 mice, most likely by directly increasing O-GlcNAcylation of tau and thereby maintaining tau in the soluble, non-toxic form by reducing tau aggregation and the accompanying panoply of deleterious post-translational modifications. These results clarify some conflicting observations regarding the effects and mechanism of OGA inhibition on tau pathology, provide pharmacodynamic tools to guide human dosing and identify CSF total tau as a potential translational biomarker. Therefore, this study provides additional support to develop OGA inhibitors as a treatment for Alzheimer’s disease and other neurodegenerative tauopathies.


Ppar Research | 2010

Kinetic assessment and therapeutic modulation of metabolic and inflammatory profiles in mice on a high-fat and cholesterol diet.

Laura W. Engstrom; Loretta A. Bober; Shu-Cheng Chen; Jay S. Fine; Ying Li; Michaela Stanton; David Kinsley; Long Cui; James V. Jackson; Alberto Rojas-Triana; Daniel Lundell; Maureen Laverty; Eric L. Gustafson; Chung-Her Jenh; Timothy J. Kowalski; Denise Manfra

The kinetics of metabolic and inflammatory parameters associated with obesity were evaluated in a murine diet-induced obesity (DIO) model using a diet high in fat and cholesterol. Cellular infiltration and mediator production were assessed and shown to be therapeutically modulated by the PPARgamma agonist rosiglitazone. C57BL/6 mice were maintained on a 45% fat/ 0.12% cholesterol (HF/CH) or Chow diet for 3, 6, 16, or 27 weeks. Flow cytometry was employed to monitor peripheral blood monocytes and adipose tissue macrophages (ATM). Gene expression and protein analysis methods were used to evaluate mediator production from total epididymal fat (EF), stromal vascular fraction (SVF), and sorted SVF cells. To investigate therapeutic intervention, mice were fed a HF/CH diet for 12 weeks and then a diet formulated with rosiglitazone (5 mg/kg) for an additional 6 weeks. A HF/CH diet correlated with obesity and a dramatic proinflammatory state. Therapeutic intervention with rosiglitazone attenuated the HF/CH induced inflammation. In addition, a novel population was found that expressed the highest levels of the pro-inflammatory mediators CCL2 and IL-6.


Biochemical and Biophysical Research Communications | 2009

Nmur1−/− mice are not protected from cutaneous inflammation

Susan J. Abbondanzo; Denise Manfra; Shu-Cheng Chen; Maria Pinzon-Ortiz; Yongliang Sun; Jonathan E. Phillips; Maureen Laverty; Galya Vassileva; Weiwen Hu; Shijun Yang; Eric L. Gustafson; Jay S. Fine; Joseph A. Hedrick

Neuromedin U (Nmu) is a neuropeptide expressed primarily in the gastrointestinal tract and central nervous system. Previous reports have identified two G protein-coupled receptors (designated Nmur1 and Nmur2) that bind Nmu. Recent reports suggest that Nmu mediates immune responses involving mast cells, and Nmur1 has been proposed to mediate these responses. In this study, we generated mice with an Nmur1 deletion and then profiled the responses of these mice in a cutaneous inflammation model utilizing complete Freunds adjuvant (CFA). We report here that mice lacking Nmur1 had normal inflammation responses with moderate changes in serum cytokines compared to Nmur1(+/+) littermates. Although differences in IL-6 were observed in mice lacking Nmu peptide, these mice exhibited a normal response to CFA. Our data argues against a major role for Nmur1 in mediating the reported inflammatory functions of NmU.


BMC Genomics | 2002

A reference database for tumor-related genes co-expressed with interleukin-8 using genome-scale in silico analysis

Lawrence Benbow; Lynn Wang; Maureen Laverty; Suxing Liu; Ping Qiu; Richard W. Bond; Eric L. Gustafson; Joseph A. Hedrick; Mitchell Kostich; Jonathan Greene; Luquan Wang

BackgroundThe EST database provides a rich resource for gene discovery and in silico expression analysis. We report a novel computational approach to identify co-expressed genes using EST database, and its application to IL-8.ResultsIL-8 is represented in 53 dbEST cDNA libraries. We calculated the frequency of occurrence of all the genes represented in these cDNA libraries, and ranked the candidates based on a Z-score. Additional analysis suggests that most IL-8 related genes are differentially expressed between non-tumor and tumor tissues. To focus on IL-8s function in tumor tissues, we further analyzed and ranked the genes in 16 IL-8 related tumor libraries.ConclusionsThis method generated a reference database for genes co-expressed with IL-8 and could facilitate further characterization of functional association among genes.


Journal of Biological Chemistry | 2003

Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein coupled receptor SP9155

Ying Jiang; Lin Luo; Eric L. Gustafson; Deepmala Yadav; Maureen Laverty; Nicholas J. Murgolo; Galya Vassileva; Ming Zeng; Thomas M. Laz; Jiang Behan; Ping Qiu; Luquan Wang; Suke Wang; Marvin L. Bayne; Jonathan Greene; Frederick J. Monsma; Fang L. Zhang


Biochimica et Biophysica Acta | 2002

The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption

Scott W. Altmann; Harry R. Davis; Xiaorui Yao; Maureen Laverty; Douglas S Compton; Li-ji Zhu; James H. Crona; Mary Ann Caplen; Lizbeth Hoos; Glen Tetzloff; Tony Priestley; Duane A. Burnett; Catherine D. Strader; Michael P. Graziano


World Journal of Gastroenterology | 2009

Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines

Mary Ann Cox; James V. Jackson; Michaela Stanton; Alberto Rojas-Triana; Loretta A. Bober; Maureen Laverty; Xiaoxin Yang; Feng Zhu; Jianjun Liu; Suke Wang; Frederick J. Monsma; Galya Vassileva; Maureen Maguire; Eric L. Gustafson; Marvin L. Bayne; Chuan-Chu Chou; Daniel Lundell; Chung-Her Jenh

Collaboration


Dive into the Maureen Laverty's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge